Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.
Riopel M, Vassallo M, Ehinger E, Pattison J, Bowden K, Winkels H, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Larson CJ, Ley K, Cabrales P, Witztum JL, Olefsky JM, Lee YS. Riopel M, et al. Among authors: bilakovics j. Mol Metab. 2019 Feb;20:89-101. doi: 10.1016/j.molmet.2018.11.011. Epub 2018 Dec 2. Mol Metab. 2019. PMID: 30553772 Free PMC article.
Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.
Riopel M, Seo JB, Bandyopadhyay GK, Li P, Wollam J, Chung H, Jung SR, Murphy A, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Koh DS, Larson CJ, Olefsky JM, Lee YS. Riopel M, et al. Among authors: bilakovics j. J Clin Invest. 2018 Apr 2;128(4):1458-1470. doi: 10.1172/JCI94330. Epub 2018 Mar 5. J Clin Invest. 2018. PMID: 29504946 Free PMC article.
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.
Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ. Farrell PJ, et al. Among authors: bilakovics j. J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19. J Pharmacol Exp Ther. 2019. PMID: 31537613
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF. Etgen GJ, et al. Among authors: bilakovics jm. Diabetes. 2002 Apr;51(4):1083-7. doi: 10.2337/diabetes.51.4.1083. Diabetes. 2002. PMID: 11916929
13 results